Stocks · News reference
JP Morgan has maintained its 'Overweight' rating on Seaport Therapeutics, Inc. and increased its price target from $40 to $41.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Seaport Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $26.4 million and highlighting key clinical milestones for its Glyph platform candidates.
Filed: 2026-11-02 AccNo: 0001193125-26-442625 Size: 339 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Seaport Therapeutics, Inc. announced its participation in the upcoming Stifel 2026 Healthcare Conference, where management will present and conduct investor meetings.
Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.